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Introduction: Gynecological malignancies (GMs) are one of the most prevalent cancers in Africa. 
Objective of this work is to review data of patients with GMs treated in Institute of Nuclear Medicine, 
Molecular Biology and Oncology (INMO)-University of Gezira -Wadmedani- Sudan, and reflect on 
characteristics of GMs in Central Sudan.  
Material and Methods: A retrospective hospital-based descriptive study was conducted to review GMs 
patients records treated in INMO from year 1999-2005. Analysis included age, residence, stage, topography 
and morphology of the cancer. 
Results: During study period GMs constituted about 20.5 percent of all women malignancies and it is the 
second commonest female cancer preceded by breast (36.7%). Most of the patients were housewives from 
rural areas of Gezira and nearby States.  The sites were ovary, 41%, cervix, 34%, uterus, 13.8%, uterine 
choriocarcinoma, 7.9%, vulva cancer, 2.9% and no single case of vaginal carcinoma was reported. The 
mean age of all patients was 52.45 years, Median age for ovarian cancer was, 50, cervix 55, uterus 55, 
Choriocarcinoma of the uterus 35 and vulva 60 years of age.  
Almost all varieties of histopathological types were seen. Fifty eight percent of patients presented with 
stage III & IV.  
Conclusions: GMs are common and present in late stages. The commonest GMs was ovarian cancer which 
affect relatively young patients. Cervix was the second common site and affect relatively older age group. 
Vulvar cancer was relatively rare and vaginal cancer was not seen. For the improvement of the outcome 
early detection, management guidelines and financial support are highly recommended.  
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:صخلملا  
ةمدقملا تاضيرملا نع تامولعملا ةعجارمل ةساردلا هذه فدهت . ايقيرفأ يف ًاراشتنا تاناطرسلا رثكأ يدحا ةثيبخلا ةيئاسنلا مارولأا ربتعت :
زجلا ةعماجل عبتي يذلا و مارولأا جلاع و ةيئيزجلا ءايحلأاو يوونلا بطلا دهعمب نهتجلاعم تمت يتلالاو  مارولأا هذهب تاباصملاةري  دوب
  يندم- . نادوسلا طساوأ يف مارولأا نم عونلا اذه صئاصخ سكعلو , نادوسلا 
ثحبلا ةيجهنم  نم ةرتفلا ىف تاونس ةتس يدم يلع دهعملل ةعباتلا تلاجسلا ىلع ًادانتسا ةيفصولا ةساردلا هذه تيرجأ :9111-5002  .
ىلا ةفاضإ مرولا لحارمو عضوم , ةماقلإا , رمعلا ليلحتلا نمضت  .ىجيسنلا هعون 
جئاتنلا  لثمت ةيئاسنلا مالاولأا نأ ةساردلا تدجو :20.5%  نم ةيناثلا ةبترملا يف يتأت يهو ةساردلا ةقطنم يف ةثيبخلا  ضارملأا عيمج نم
 تلثم يتلا و يدثلا ةناطرس دعب عويشلا ثيح36.7%  و ةريزجلا ةيلاول ةيفيرلا قطانملا نمو لزانم تابر نك تاديسلا بلغا . تايلاولا
 : يتلأاك ضرملا عضاوم تناك . اهل ةرواجملا 
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 ضيبملا ىف19%   ،34%   ،محرلا قنع يف31.8%   ،محرلا يف7.9%  و هيئاميشم هناطرس2.9%  ةدحاو ةلاح دجوت مل امنيب جرفلا يف
 تاديسلا عيمج يف رمعلا طسوتم نأ ةساردلا تحضوأ لبهملا ةناطرسل52.5 ضاوملا بسح  طيسولا و اماع  ضيبملا ةناطرس : يتلأاك ع
50  محرلا قنع ,55  محرلا ,55 ةيئاميشلا ةناطرسلا ,35  جرفلا و60. مارولأا هذهل ةضيملا ةجسنلأا عاونأ عيمج تدهوش . ًاماع 
ةساردلا ةصلاخ. ًايبسن رمعلا ىف تاريغص تاديس بيصتو ًاعويش عاون لأا رثكأ  ىه ضيبملا ةناطرس  : 
 تأت محرلا قنع ةناطرس ةلاح ىأ لجست ملو ثودحلا ةردان جرفلا ةناطرس . ًايبسن ةريبك نهرامعأ تاباصملا تاديسلا و ةيناثلا ةبترملا ىف ى
 لئلاد مادختساو ضرملل ركبملا فاشتكلاا يلع لمعلاب ةساردلا يصوت ضرملا لبقتسمو ةجلاعملا جئاتن نيسحتل .لبهملا ةناطرس تلااح نم
 ةفاضلإاب ةجلاعملا يف ةيداشرإ. يموقلا معدلا باطقتسا  يلإ 
Introduction: 
Cancer is a notorious disease claiming lives of over 7.6 million inhabitants of the globe in 2005, 
70% of deaths occur in low and middle income countries 1. Different sites of female genital system are 
affected by cancer and they differ in incidence, risk factors, clinical presentation, histology and treatment 
modalities. The major sites of genital malignancies in female are ovaries, uterus, cervix, vagina, and vulva. 
Distribution of gynecological malignancies is very much different across different nations 2. 
Diversity in distribution may be related to multi-factorial issues including people culture, education, health 
services, socioeconomic status and genetic factors. In developing countries generally all these factors are 
unfavorable and poor. 
In Africa GMs are the leading cancers and cervix cancer is by far the most common.  Cervical cancer 
is the second commonest women cancer worldwide with very high incidence and mortality in Africa and 
Latin America 3. Cervical cancer incidence is not high in USA compared to Africa and Latin America 4, 5. 
More than 80% of world cervical cancer in 2002 occurred in developing countries with a fatality up to 85% 
6 . 
Incidence of cancer in Sudan is difficult to estimate due to lack of population-based cancer registry. 
The aim of this study is to estimate the burden of GMs in the Central Sudan and to look for the pattern of 
GMs in this region. Although this is a hospital-based study but it gives rough estimation about the 
magnitude and the general epidemiological features of GMs in Central and Eastern parts of the Sudan. 
 
Method: 
This is a retrospective descriptive review carried out for all patients with GMs who presented to 
INMO during May 1999- April 2005 reviewing hospital records. This work was done by the team of a 
combined Gyne-oncology clinic (CGC) which was established in 2005. All new cases are usually seen by 
the CGC for staging and treatment planning. All records were located in the statistics and information 
department in INMO.  
INMO is one of the two cancer centers available in Sudan, established in 1999, and it belongs to 
University of Gezira, which is located in Wadmedani city. Wadmedani lies on the west bank of Blue Nile 
about 188 kilometers south to the capital, Khartoum. It is the Capital of Al-Gezira State which is one of 
heavily populated states in Sudan (nearly 40 million inhabitants). The catchment areas includes, in addition 
to Gezira state,  most of Central and Eastern States of the Sudan. INMO provides most of the known kinds 
of cancer treatments as well as palliative care for all cancer patients who are referred from different 
secondary and tertiary hospitals.  
Parameters included in the analysis were patient age, residence, cancer topography, histology and 
stage. Cases diagnosed with choriocarcinomas were included in the analysis except for stage, due to its 
special mode of evaluation for treatment and prognostic criteria. Inclusion criteria covered all cases referred 
to INMO if they had been treated before or not. The only exclusion criteria were the cases that had been 
referred before or after study period.   
SPSS soft ware was used for data entry and analysis. No record of GM was excluded from this 
review. The results are tabulated and presented in a simple percentage form. 
Results: 
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A total of 273 records were found and all were reviewed. Most of cases were from the Gezira state 
accounting for 75.3% of all cases. Patients from rural areas were dominant in this study and represented 
72.4% of cases. 
Topography: 
The commonest site affected among all cases was the ovary which represented 38.5% of all cases. 
The cervix came in the second order of sites with (33.5%). Others in order of frequency were uterus 
(14.5%), and vulva (4%). No single case of vaginal cancer was seen. A separate entity originated in 
gestational Trophoblast is Choriocarcinoma, which constitute 8.4% of all cases. 
Age: 
The Median age for ovarian cancer cases seen was 50 years of age, range was 12-85 years and the 
mean was 51. Median age for cervix was 55 years of age, age range was 25-95 years and the mean was 55.4 
years. For uterine cancer the median age was 55 years, age range was 28-78 years and the mean was 54.3 
years. The vulvar cancer mean age was 60 years and age range was between 40-80 years. Choriocarcinoma 
median age was 35 years, range was 18-45 years and the mean was 32.9 years. Patients' characteristics 
according to site are shown in table 1. 
Histology: 
The commonest histology seen in ovarian malignancies was the epithelial type (82.2%); other very 
less common histology was germ cell tumors (5.6%). For the cervix the squamous cell carcinoma accounted 
for 91.3% of all cases and adenocarcinoma was seen in 6.5%. Adenocarcinoma in the uterus accounted for 
75% of cases and Sarcoma was seen in 22.5%. Almost 96% of Vulva cancer cases were squamous cell 
cancer type. 
Stage:  
Table 2 summarizes stage at presentation for ovary, cervix, uterus, and vulva cancers. In general the cases 
presented in late stages (III/IV) accounting for 58% of all cases. Cases without known stage were 10.8%. 
Less than one third of ovarian and cervical cancer cases present in early stages (I/II). Surprisingly, only 
27.5% of uterine cancer cases present in early stage. Table 2 showed different stage groups.  
 
Discussion: 
GMs are more common in developing than developed World, but still breast cancer precedes GMs 
in both worlds. In Sudan breast is by far the commonest female cancer and constitutes more than one third 
of all female cancers treated in INMO. Breast cancer is more frequent than all GMs collectively and exceeds 
one third of all women treated in INMO (from annual reports of statistic and information department-
INMO)-Fig 1. GMs in this study, taken from cases treated at one center over 6 years, showed that they are 
less than what seen in Africa where cervical cancer constitutes about 15% of all women malignancies 7. In 
this series of patients', ovarian malignancy was more dominant than cervical cancer, in contrast to the other 
only center for cancer in Sudan- Radiation and Isotopes Center- Khartoum (RICK), in which cervix cancer 
was found to precede ovarian cancer 8. In Africa the cervix cancer is dominant as reported from countries 
like Nigeria, where cervix cancer is the commonest GMs 9.  
The ovarian cancer is the most frequent cancer in this region, the age is different compared to a 
developed country like UK where the incidence is low under 40 years-of age, but rises dramatically through 
fifth decade. The maximum incidence in UK occurs in 80-84-years old group 10. In this study a quarter of 
the reviewed patients were below 40 years of age. The maximum incidence occurs in the 40-60-years old 
group. A reason for young age group may possibly be due to the short life span of Sudanese women (life 
expectancy 62 years) masking incidence in old ages. Potential genetic factors may play a role in explaining 
the high incidence in this young age group in the population of this region of Sudan. One should not exclude 
some environmental factors as well. Late presentation is not differing from that seen worldwide because of 
the nature of this disease (silent killer).  
Cervix cancer is second to ovary in this series. Statistics from RICK, showed cervical cancer 
predominance, but it is again a hospital-based study 8. Cervix cancer is the leading women cancer in Sub-
Saharan Africa, Central America and South-central Asia preceded only by breast cancer 7. Fifteen percent 
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of female cancers in the developing countries are cervical while in developed world it constitutes only 3.6% 
of all cancers7. In North America, Europe and Australia the incidence is low but, before screening 
programme in 1960s and 1970s the incidence was similar to developing countries 11. In China incidence is 
five times higher than developed countries and majority present with late stage of disease 12. In Brazil the 
incidence is estimated at 26.28 cases per 100 000 women 6. The lowest recorded rate of cervix cancer is 0.4 
per 100.000 in Ardabil, Northwest Iran 13. 
Late presentation reflects the lack of screening in Sudan. The age pattern of cervix cancer in this 
study population was different from what reported in the literature. Younger age was seen in Brazil, where 
the mean age for cervix cancer was 37.4 years with a range of (14-91years) 5. Median ages, in some studies 
from United States and UK is 10 years lower than this series, and in India it is 20 years lower than this 
study population age 14, 15. Cervix is less common than ovary in this region not because there is screening 
programme, but may be due to the conservative community in this part of Sudan, where sexual life is limited 
to married partners at most, almost all the inhabitants of central and eastern states of Sudan are Arab, 
Moslems, and share same traditions and customs. Studies considered cervix cancer as a sexual transmitted 
disease with human Papilloma virus being the major etiological factor 15, 16, 17. The prevalence shown is this 
study for cervix is similar to Middle-East region that may be due to similarity of population culture. 
Uterine cancer order of ranking in this series of patients is similar to reports from Western world, 
but the median age is lower. Uterine cancer constitutes 2% of all women cancers in USA and it ranks third 
in GMs, preceded by ovary and Cervix, with a median age of 63 years 18. Strikingly cases in this series 
presented in late stages of disease unlike reports from the West where uterine cancer is considered one of 
the cancers which presents in early stages and mostly curable 18. Post menopausal bleeding is an early 
symptom for endometrial cancer, but in this region of Sudan probably patients, patients' relative and 
possibly treating doctors tend not to take this warning sign seriously.  Choriocarcinoma is not uncommon 
and affecting young age group with features similar to reports from other developing countries. It is a rare 
tumor in western countries; the incidence is 1 in 45,000 pregnancies. Higher incidence is reported from, 
Africa, Asia and South America. Majority of cases occur in women aged less than 35 years of age 19. 
Carcinoma of the Vulva was the least common and this is similar to international data, we report median 
age at presentation lower than what was reported from Sweden 20. 
During the period of this study we couldn't come across a single case of vaginal cancer and this 
reflects it is an extremely rare disease in this region of Sudan. 
All histological types of GMs were seen and they weren't different from usual known pattern in 
literature. Untagged patients explain the difficulties in management of GMs in Sudan. This is possibly due 
to the shortage of gynecological oncologists, the lack of advanced investigational service and management 
guidelines. There is a general agreement that combined clinics are the best way to manage cancer, it is 
worth mentioning that in INMO there is now a working combined GMs clinic since May 2006.  
 
Conclusion: 
GMs are common in Sudanese female population and tend to present in late stages. Ovary cancer is 
the leading GMs in this region and affects young age group. Cervix cancer affects relatively older age group 
and is less common compared to the other parts of Sudan, Africa and Latin America. Introduction of 
screening programme and establishment of population -based cancer registry are recommended. Studies for 
identification of possible risk factors and treatment outcome are important. 
 
Acknowledgement: 
We would like to thank the staff of statistic and medical records in INMO for their unlimited 
patience and cooperation during data collection and processing. Also special thanks to the assisting team 
of nursing staff working in CGC. 
 
 
Table (1) patients characteristics according to site.  
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patients characteristic Number (%) Histology (%) 
Site 
   Ovary 
   Cervix 
   Uterus 
   Vulva 








Epithelial cancer (82.2) 
Squamous cancer (91.3) 
Adenocarcinoma (75) 
Squamous cancer (96) 
 Age 
   Ovary 
   Cervix 
   Uterus 
   Vulva 














* GTT = Gestational trophoblastic Tumors. 
 
Table 2: Stage groups of different sites.  
 























Fig (1): The commonest 10 female cancers- Annual report- 1999-2005 - (INMO)  
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